-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-24
The 2023 reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its inhibition to reduced renal fibrosis, inflammation, and epithelial–mesenchymal transition. Using AZ505 and LLY507 in animal and tubular epithelial-cell models, the authors connect these effects with altered Smad3, STAT3, and Smad7 signaling, while also defining important limits for translation.
-
Dimethyloxalylglycine (DMOG) Protocol Guide
2026-08-23
Dimethyloxalylglycine (DMOG), SKU A4506, provides a practical way to investigate hypoxia-inducible factor stabilization and related oxygen-sensing responses under normoxic culture conditions. It is intended for controlled in vitro and preclinical in vivo research, not for diagnostic, therapeutic, or medical use.
-
Mianserin HCl–Cyclodextrin Complexation
2026-08-22
The reference study shows that methylated β-cyclodextrin forms measurable host–guest complexes with mianserin hydrochloride but does not reduce its cytotoxicity in B14 cells. Its combined calorimetric, spectroscopic, mass-spectrometric, docking, and cell-based approach demonstrates why improved solubility should not be interpreted as improved biological safety.
-
Tamoxifen Workflows for CreER and Cancer Research
2026-08-22
Tamoxifen is a versatile selective estrogen receptor modulator for conditional genetics, breast cancer research, and immune-oncology assays. This guide connects practical formulation and assay design with a recent study showing that tamoxifen can improve radiation responses by reprogramming tumor-associated macrophages.
-
Spermine Tetrahydrochloride in Translational Biology
2026-08-21
Spermine tetrahydrochloride is more than a polyamine additive: its charge-driven behavior connects membrane stabilization, protein crystallization, and polymer nanoparticle engineering. This thought-leadership article explains how translational researchers can use the reagent strategically, interpret the DDX3 structural biology precedent, and avoid overextending evidence into NMDA receptor or therapeutic claims.
-
Cefazedone (Refosporen) Research Workflows
2026-08-20
Cefazedone (Refosporen) supports reproducible broth-dilution, MIC, and time-dependent PK/PD workflows spanning Gram-positive and Gram-negative bacterial infections. This guide translates its solubility limits, exposure benchmarks, and clinical pharmacodynamic evidence into practical assay design and troubleshooting decisions.
-
EZ Cap™ Cas9 mRNA (m1Ψ) Workflow
2026-08-20
Build transient CRISPR-Cas9 experiments around Cap1-capped, m1Ψ-modified Cas9 mRNA for responsive editing in mammalian cells. This practical guide connects RNA handling, delivery, specificity testing, and the reference study’s mRNA-export insight to help distinguish poor delivery from excessive Cas9 exposure.
-
Tubastatin A: HDAC6 Inhibitor Workflows
2026-08-19
Tubastatin A links selective HDAC6 inhibition with microtubule stabilization, inflammatory control, and programmed-cell-death analysis. This practical guide translates porcine cardiac-arrest evidence into adaptable workflows for cancer biology, inflammation, neuroprotection, and cell-based mechanism studies.
-
Staurosporine and the Near-Death Metastasis Assay
2026-08-19
Staurosporine is more than an apoptosis trigger: it can help researchers separate acute kinase-dependent cell death from stable prometastatic states. This article translates recent PAME findings into practical assay and cancer research decisions.
-
Indometacin and Premature Ovulation in IVF
2026-08-18
This randomized, double-blind trial tested whether adding indometacin to modified natural-cycle IVF could reduce premature ovulation before oocyte retrieval. The overall difference was not statistically significant, but a prespecified clinical subgroup without an LH surge at human chorionic gonadotrophin administration showed a signal of benefit, supporting more selective rather than routine use in future studies.
-
JC-1 Mitochondrial Membrane Potential Assay
2026-08-18
The JC-1 Mitochondrial Membrane Potential Assay Kit provides ratiometric mitochondrial membrane potential assay data through red aggregate and green monomer fluorescence. K2002 includes a CCCP control and supports cellular, tissue, and purified mitochondrial samples for apoptosis assay and mitochondrial function analysis.
-
IL-17A, CSMC Senescence, and Neurogenic ED
2026-08-17
Yang et al. identify IL-17A as a central driver of corpus cavernosum fibrosis after denervation and connect this cytokine to CSMC senescence through the mTORC2–ACACA pathway. The study combines molecular profiling, cell-based validation, mechanistic perturbation, and rat intervention experiments to show that interrupting IL-17A-associated senescence can improve erectile function and reduce fibrosis.
-
Tropisetron Hydrochloride: Assay Workflows
2026-08-17
Tropisetron Hydrochloride supports paired studies of 5-HT3 receptor blockade, α7-nicotinic receptor signaling, and renal organic-cation transport. This workflow-focused guide shows how to separate receptor pharmacology from OCT2/MATE1 transporter effects and troubleshoot common assay failures.
-
Cancer Drug Responses: Growth Arrest vs Cell Death
2026-08-16
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug activity. Its central practical contribution is a time-aware framework for separating proliferative arrest from actual cell killing, improving interpretation of in vitro drug-response experiments.
-
LY2228820: p38 MAP kinase inhibitor workflows
2026-08-15
LY2228820 enables targeted interrogation of p38α/β signaling across inflammation, oncology, cytokine, and angiogenesis assays. This workflow-focused guide connects phospho-MK2 measurements with combination cytotoxicity, apoptosis assay design, solubility control, and a newer phosphatase-aware interpretation of p38 inhibition.